A Novel Approach to the Treatment of IgA Nephropathy
IgA Nephropathy is a rare, progressive autoimmune disease characterized by glomerulonephritis and an accumulation of galactose-deficient IgA1-containing immune-complexes that may cause progressive deterioration of renal function and risk of progression to end-stage kidney disease. Current KDIGO guidelines recommend providing maximal supportive care using RASi for all patients with proteinuria >0.5 g/day. Systemic glucocorticoid therapy is suggested but not recommended. Evidence on the role of the gut mucosal immune system in IgA Nephropathy has evolved, impacting the role of future therapies.
This program will review:
- The 4-hit hypothesis, gut-kidney axis, and its role in IgA Nephropathy pathogenesis
- The burden of IgA Nephropathy and risk of deterioration of renal function in patients with IgA Nephropathy
- Appropriate management of patients based on current KDIGO guidelines
- A novel FDA-approved treatment option for patients with IgA Nephropathy
Speaker:
Shikha Wadhwani, MD, MS
Assistant Professor of Medicine
Division of Nephrology and Hypertension
Northwestern University
Feinberg School of Medicine
This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.
Sponsored by:
For individuals from the media/press who are interested in attending, please email media@amcp.org.
